Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18308653 | 0.89 | FOLH1 (0.60) | FOLH1EPHX2ITGB3ITGAVCPB1 | |
| SCHEMBL15107348 | 0.88 | FOLH1 (0.78) | FOLH1 | |
| SCHEMBL18307317 | 0.88 | FOLH1 (0.52) | FOLH1 | |
| SCHEMBL17190068 | 0.85 | FOLH1 (0.58) | FOLH1EPHX2ITGB3ITGAVCPB1 | |
| SCHEMBL18307319 | 0.83 | FOLH1 (0.61) | FOLH1EPHX1 | |
| SCHEMBL12193062 | 0.81 | ATM (0.68) | FOLH1EPHX2ANPEPEPHX1 | |
| SCHEMBL15107349 | 0.79 | FOLH1 (0.78) | FOLH1 | |
| SCHEMBL15739460 | 0.79 | FOLH1 (0.69) | FOLH1 | |
| SCHEMBL12252067 | 0.78 | MAPT (0.69) | ANPEPEPHX1 | |
| SCHEMBL8853611 | 0.78 | ALDH1A1 (0.56) | FOLH1CPB1CPB2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885EPHX2 1280/4885ITGB3 271/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885EPHX2 1280/4885ITGB3 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.